Mirati Therapeutics, Inc. Sustainability Profile
Mirati Therapeutics, Inc., a leading biotechnology company headquartered in the United States, focuses on the development of innovative therapies for cancer treatment. Founded in 2010, Mirati has made significant strides in the oncology sector, particularly in targeted therapies and precision medicine. The company is renowned for its core products, including novel small molecule inhibitors that address specific genetic mutations in tumours, setting it apart in a competitive landscape. With a strong emphasis on research and development, Mirati has achieved notable milestones, including advancing multiple candidates into clinical trials. As a key player in the biotechnology industry, Mirati Therapeutics continues to enhance its market position through strategic partnerships and a commitment to transforming cancer care, making it a pivotal entity in the fight against cancer.
DitchCarbon Score
How does Mirati Therapeutics, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Mirati Therapeutics, Inc.'s score of 69 is higher than 80% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Mirati Therapeutics, Inc., headquartered in the US, currently does not report specific carbon emissions data, as indicated by the absence of emissions figures. The company is a current subsidiary of Bristol-Myers Squibb Company, which influences its climate commitments and initiatives. Mirati's climate strategy is informed by the sustainability efforts of its parent company, Bristol-Myers Squibb. This includes participation in various climate initiatives such as the Science Based Targets initiative (SBTi) and the Carbon Disclosure Project (CDP), both of which are cascaded from Bristol-Myers Squibb. However, specific reduction targets or achievements for Mirati Therapeutics are not detailed in the available data. As part of its corporate family, Mirati is aligned with industry-standard climate terminology and practices, although it has not set its own distinct reduction targets or climate pledges at this time. The company's commitment to sustainability is thus closely linked to the broader initiatives of Bristol-Myers Squibb, reflecting a collective approach to addressing climate change within the pharmaceutical sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 210,540,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 150,790,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | 69,630,000 | 00,000,000 | 00,000,000 | 00,000,000 | 000,000,000 | 00,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
How Carbon Intensive is Mirati Therapeutics, Inc.'s Industry?
How Carbon Intensive is Mirati Therapeutics, Inc.'s Location?
Mirati Therapeutics, Inc.'s Scope 3 Categories Breakdown
Mirati Therapeutics, Inc.'s Scope 3 emissions, which decreased by 1% last year and increased significantly since 2015, demonstrating supply chain emissions tracking. The vast majority of their carbon footprint comes from suppliers and value chain emissions, representing the vast majority of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 77% of Scope 3 emissions.
Top Scope 3 Categories
Mirati Therapeutics, Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Mirati Therapeutics, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
